Virology testing
consist of diagnostic methods that help in early detection of the disease such
as hepatitis, influenza, HIV, sexually transmitted disease, RCV, and other
viral associated disease. Virology testing examines for detection of viral
antigens, nucleic acids, and antibodies in the given sample in order to confirm
the presence of particular viral infection. There are more than 100 viral
diseases identified.
Virology Testing Market- Market Dynamics
Virology testing market is projected to witness significant growth
during forecast period with rising prevalence of virus originated diseases such
as flu, hepatitis, AIDS, and STDs, Ebola, Influenza based viral infections,
severe acute respiratory syndrome from coronavirus, hemorrhagic fever etc.
across world. Early and fast diagnosis of virus infection is very essential to
start treatment course.
According to the World Health Organization (WHO), January 2018
factsheet, all types of influenza in combination causes annual epidemics about
3 to 5 million cases with severe stage of illness, which results in the
290 000 to 650 000 deaths worldwide annually. Although rapid diagnostic
tests are majorly used, PCR based techniques are being adopted for detection of
influenza.
According Report on Global Sexually Transmitted Infection Surveillance
published in 2015 by WHO, in 2012, an estimated 357 million new infections,
which is equivalent to roughly 1 million patients per day were reported for the
four curable sexually transmitted disease such as chlamydia, gonorrhea,
syphilis, and trichomoniasis.
Virology Testing Market - Regional Insights
On the basis of Geography, virology
testing market is segmented into North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa. North America is projected to dominate the
virology testing market over the forecast period. According to the Centers for
Disease Control and Prevention (CDC), around 5,251 deaths were reported due to
influenza infection in 2015.
According to the National Ambulatory Medical Care Survey: 2015 data
findings, around 16.8 million people visit to physician for treatment of
infectious and parasitic diseases in U.S. Moreover, according to a study from
the Society for Risk Analysis, 2016, GDP loss of a viral pandemic outbreak in
the U.S. was recorded between US$ 34.4 billion and US$ 45.3 billion in 2015.
Comments
Post a Comment